Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs.

@article{Genin1996SynthesisAB,
  title={Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs.},
  author={Michael J. Genin and T J Poel and Yasuo Yagi and Charlie Biles and Irene W. Althaus and B J Keiser and Laurice A Kopta and Janice M. Friis and Fritz Reusser and Wade J. Adams and Robert A. Olmsted and Richard L Voorman and Richard C. Thomas and Donna Lee Romero},
  journal={Journal of medicinal chemistry},
  year={1996},
  volume={39 26},
  pages={
          5267-75
        }
}
The major route of metabolism of the bis(heteroaryl)piperazine (BHAP) class of reverse transcriptase inhibitors (RTIs), atevirdine and delavirdine, is via oxidative N-dealkylation of the 3-ethyl- or 3-isopropylamino substituent on the pyridine ring. This metabolic pathway is also the predominant mode of metabolism of (alkylamino)piperidine BHAP analogs (AAP-BHAPs), compounds wherein a 4-(alkylamino)piperidine replaces the piperazine ring of the BHAPs. The novel AAP-BHAPs possess the ability to… CONTINUE READING